Cellectis Launches Ectycell Subsidiary Dedicated to Stem Cells Applications
Cellectis S.A. has announced the incorporation of Ectycell, a subsidiary dedicated to the biomedical uses of stem cells. The initial applications developed are (i) tools for generating induced pluripotent stem cells from adult cells, (ii) robust, reproducible differentiation of stem cells and (iii) the constitution of cell libraries for testing drug candidates.
"Cellectis' core technologies will have a major impact on the stem cell field", stated David Sourdive, CEO of Ectycell. "We are tackling important issues here, such as reducing the high attrition rate in drug development by using early-stage assays that better predict a molecule's effect on the organism as a whole or on a genetically diverse population. We also may have the opportunity to open new paths for regenerative medecine - especially for pathologies like Alzheimer's and Parkinson's diseases".
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.